Compare UHS & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHS | WST |
|---|---|---|
| Founded | 1978 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 16.6B |
| IPO Year | N/A | N/A |
| Metric | UHS | WST |
|---|---|---|
| Price | $232.94 | $242.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $231.62 | ★ $328.00 |
| AVG Volume (30 Days) | 637.4K | ★ 1.2M |
| Earning Date | 02-25-2026 | 02-12-2026 |
| Dividend Yield | 0.35% | ★ 0.36% |
| EPS Growth | ★ 39.76 | 0.17 |
| EPS | ★ 21.01 | 6.75 |
| Revenue | ★ $16,992,503,000.00 | $3,017,900,000.00 |
| Revenue This Year | $10.92 | $6.97 |
| Revenue Next Year | $4.96 | $6.27 |
| P/E Ratio | ★ $11.01 | $36.46 |
| Revenue Growth | ★ 10.21 | 4.92 |
| 52 Week Low | $152.33 | $187.43 |
| 52 Week High | $246.33 | $325.20 |
| Indicator | UHS | WST |
|---|---|---|
| Relative Strength Index (RSI) | 69.65 | 44.51 |
| Support Level | $211.00 | $243.47 |
| Resistance Level | $220.42 | $252.57 |
| Average True Range (ATR) | 7.64 | 9.89 |
| MACD | 3.66 | 1.72 |
| Stochastic Oscillator | 75.56 | 51.26 |
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.